News and Reports
-
Upstream Bio Presents New Phase 1 Clinical Data on UPB-101 at the American Thoracic Society (ATS) International Conference
22 May 2023Download -
Numab Therapeutics Announces First Subject Dosed in Phase 1 Clinical Study of NM26 Program
15 May 2023Download -
Swixx and Beigene Partner in 13 Countries of Central and Eastern Europe, Greece, Cyprus and Malta
9 May 2023Download -
SphingoTec's Innovative IVD Product sphingotest® penKid® Receives First IVDR Certificate
9 May 2023Download -
Antiva Biosciences Closes $53 Million Series E Equity Financing Led by MPM-BioImpact Capital and Names Kristine Ball President and CEO
27 April 2023Download -
Sai Life Sciences opens SSRL, a dedicated research facility for Schrödinger, at its Hyderabad R&D Campus
20 April 2023Download -
ArriVent Biopharma Closes $155 Million Oversubscribed Series B Financing
27 March 2023Download -
Mineralys Therapeutics Announces Pricing of Upsized Initial Public Offering
9 February 2023Download -
Neuron23 Announces First-in-Human Dose in Phase 1 Clinical Trial of its Best-in-Class Brain-Penetrant LRRK2 Inhibitor for Parkinson’s Disease
7 February 2023Download -
SWIXX and BioCryst partner for ORLADEYO® (berotralstat) in Central and Eastern Europe
24 January 2023Download -
SWIXX and Jazz Pharmaceuticals expand partnership with agreement to now distribute EPIDYOLEX® (CANNABIDIOL) in CEE territory
20 January 2023Download -
Sai Life Sciences inks strategic agreement to set up Schrödinger’s first dedicated offshore Research Laboratories in India
10 January 2023Download -
SWIXX and Kyowa Kirin expand Partnership for Rare Disease Portfolio to 13 Countries in Europe
19 December 2022Download -
Mineralys Therapeutics Announces Positive Topline Phase 2 Data for MLS-101 in the Target-HTN Trial Evaluating the Treatment of Uncontrolled and Resistant Hypertension
16 November 2022Download -
Boditech Med and SphingoTec close global licensing agreement for kidney function biomarker Proenkephalin A 119-159 (penKid)
15 November 2022Download -
Swixx and Kyowa Kirin enter into Partnership for Rare Disease Medicines Portfolio in Poland
10 October 2022Download -
Shape Memory Medical Completes Enrollment in the AAA-SHAPE Early Feasibility Study
29 August 2022Download -
Upstream Bio Announces Dosing of First Patient in a Phase 1b Clinical Trial of UPB-101 in Asthma
9 August 2022Download -
Vascular Dynamics Completes $20 Million Equity Financing to Support Further Clinical Evaluations of MobiusHD Device
12 July 2022Download -
Galera Announces Results from Phase 1 Stage of GRECO-1 Trial of Rucosopasem with SBRT for NSCLC
29 June 2022Download -
Aculys Pharma initiates collaboration with Ubie with the aim of building a “sleep ecosystem”
29 June 2022Download -
Akoya Biosciences to Partner with Acrivon Therapeutics for the Clinical Development of Acrivon’s Proprietary OncoSignature® Test into a Companion Diagnostic
28 June 2022Download -
Acrivon Therapeutics Receives FDA Clearance for Innovative Phase 2 Trial to Treat Ovarian, Endometrial and Urothelial Cancer Patients Based on Predicted Sensitivity to ACR-368
22 June 2022Download -
Galecto Announces First Patient Enrolled in Phase 2 Trial of GB1211 in Combination with Atezolizumab for First-Line Treatment of NSCLC
16 June 2022Download -
Dren Bio Announces $65 Million Series B Financing to Advance its Lead Asset into the Clinic
14 June 2022Download